Partner, Third Rock Ventures
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Founder and Managing Partner, Frazier Healthcare Ventures
Managing Director, D.E. Shaw and Co., L.P.
Professor, Michigan State University
Vice President for Research at UT Health Science Center at San Antonio
Professor of Systems Biology, Columbia University
Senior health advisor for Esri
Alexion Pharmaceuticals’ flagship drug has made a strong case it can treat yet another rare disease, and the company is now mapping out plans to file for approval in the U.S. and other regions.
The Boston company released preliminary Phase 3... Read more »
With fall officially here, it’s time to ask some big questions about the coming year—and decade.
What will be the most transformative technology areas for society and business? What should students and innovators be doing to prepare for five to 10... Read more »
Many large drug companies go to extraordinary lengths to fend off generic competition and extend the life of their patents, but Gilead today announced a highly unusual move in the opposite direction. In January 2019, the company will start selling “authorized”... Read more »
There was more news this morning in the advancement of precision cancer drugs, which target a tumor’s genetic signature. Roche plans to file for approval of entrectinib, a drug the Swiss firm acquired when it bought San Diego, CA-based Ignyta for... Read more »
Can fish oil help prevent, or reduce the risk of heart disease? Several studies have failed to show that it can. But Amarin this morning is releasing data from a massive study showing that its prescription-grade fish oil pill, Vascepa, has... Read more »
Marketo almost didn’t get off the ground.
It was 2006, and Jon Miller and his Marketo co-founders were struggling to raise money from investors for their marketing technology startup. Their pitch was to use software to help businesses automate much of... Read more »
Equillium, a biotech startup developing treatments for immune system disorders—including an immune response that affects some transplant recipients—is preparing for an IPO to finance tests of its lead drug.
The company set a preliminary IPO target of $86 million, according to... Read more »
TitleTownTech, a soon-to-be-launched joint venture between the NFL’s Green Bay Packers and tech giant Microsoft, has hit the brakes on a startup accelerator the two organizations had previously said they planned to run together.
Craig Dickman, whom the Packers named... Read more »
Sigstr, the Indianapolis-based marketing tech startup, announced this week that it has raised $4 million in new venture funding. The round was led by Edison Partners, with participation from past investors, including Hyde Park Venture Partners, HubSpot Ventures... Read more »
Cancer drug developer Y-mAbs Therapeutics is the latest biotech company to go public, raising $96 million in its IPO.
New York-based Y-mAbs priced its offering of 6 million shares at $16 each, which was the high end of its projected range.... Read more »
Tech giant Adobe announced Thursday it is buying marketing-software firm Marketo for $4.75 billion. The move may have a ripple effect on the realm of enterprise sales and marketing.
Marketo, based in San Mateo, CA, was founded in 2006 and built... Read more »
Sarepta Therapeutics won one of the most controversial drug approvals in recent memory, when the FDA in September 2016 approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) off a slim set of data. The Cambridge, MA, company isn’t having the... Read more »
Biotech company uBiome started as a “citizen science” project that collected and studied microbiome samples in order to learn how the trillions of bacteria living in and on people’s bodies affect human health.
Six years and 250,000 samples later, uBiome is... Read more »
San Antonio — Life science groups, city officials, and research institutes in San Antonio are organizing an effort to commercialize more scientific developments coming out of the city’s military organizations.
The goal of the project is to develop an alliance between... Read more »
The U.S. Senate had a rare moment of agreement, overwhelmingly passing a package of opioid-related bills. Up the East Coast, life-science players in Rhode Island are working to bring different local factions together and boost the state’s economy. Across the country,... Read more »
Convoy, an online marketplace that connects shippers with freight truck fleets and independent drivers, announced today it raised $185 million in a Series C fundraising round led by CapitalG, the growth equity investment fund of Alphabet, Google’s parent company.
With... Read more »
Technology has been transforming the way we work for decades, and MIT believes figuring out how to leverage it to rethink jobs and community prosperity is a grand technological challenge of our time. To respond to what the university calls an... Read more »
Elanco is now a standalone company after raising $1.5 billion in its stock market debut.
Greenfield, IN-based Elanco (NYSE: ELAN) sold 62.9 million shares at $24 apiece, which topped the $20 to $23 range it had initially targeted. Investors showed... Read more »
[Updated 9/20/18, 1:04 pm. See below.] Cybersecurity software firm Rapid7 is rolling out new and updated products geared toward helping customers automate more of their security processes and tie together the patchwork of defense mechanisms many of them have... Read more »
Catch up on news from Wisconsin’s innovation community with these recent headlines:
—The NFL’s Green Bay Packers said Craig Dickman has been named managing director of TitleTownTech, a joint venture between the team and Microsoft that’s aimed at spurring digital-age... Read more »
Kim Gamez, CEO and co-founder of the Ann Arbor, MI-based startup Mi Padrino, is a self-described “all-American Gringa” who grew up in farm country. She fell in love with Hispanic culture as she got to know her husband Hugo,... Read more »
Fresh off finally winning an FDA nod for its first product, Amicus Therapeutics is getting in on the gene therapy renaissance.
This morning, Cranbury, NJ-based Amicus (NASDAQ: FOLD) agreed to pay $100 million up front to buy a privately held... Read more »
President & CEO, Indiana Biosciences Research Institute
CEO and Fund Manager, Renaissance Venture Capital Fund
Director, Silicon Flatirons Centers' Entrepreneurship Initiative
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
